The impact of ruxolitinib treatment on inflammation‐mediated comorbidities in myelofibrosis and related neoplasms

Abstract

The inflammation‐mediated comorbidities in myelofibrosis ( MF ) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK 1‐2 inhibitors in MF ‐patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation‐mediated comorbidities.